Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04051333 · ClinicalTrials.gov registry record

The E-health Application To Modify ORal Energy Intake and Measure Outcomes REmotely in ALS Clinical Trial (EAT MORE2)

A clinical trial of Amyotrophic Lateral Sclerosis, sponsored by Massachusetts General Hospital.

Completed
Registry status
87
Enrollment target
1
Study location

NCT04051333 is a study of Amyotrophic Lateral Sclerosis that has completed, run by Massachusetts General Hospital. The registered enrollment target is 87 participants, below the 897-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04051333, a study of Amyotrophic Lateral Sclerosis, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
87 participants
Enrollment target
1
Study location

Study Summary

This is phase IIa feasibility and tolerability study of a mobile health (mHealth) application designed to study the effects of remote dietary counseling on disease progression and quality of life. The study will consist of two phases: Part I will consist of building and beta-testing the ALS Nutrition app and Part II will consist of enrolling a larger cohort of users into the app.

Interventions

  • DEVICE ALS Nutrition App (MyDataHelps platform)

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 87 participants
Start Date 2020-03-30
Est. Completion 2021-12-31

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT04051333

The ClinicalTrials.gov registry entry for NCT04051333 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 897-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (90% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which ALS Nutrition App (MyDataHelps platform) is the first listed.

NCT04051333 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04051333 about?

NCT04051333 is a clinical study titled "The E-health Application To Modify ORal Energy Intake and Measure Outcomes REmotely in ALS Clinical Trial (EAT MORE2)". This is phase IIa feasibility and tolerability study of a mobile health (mHealth) application designed to study the effects of remote dietary counseling on disease progression and quality of life. The study will consist of two phases: Part I will consist of building and beta-testing the ALS Nutritio...

What is the current status of trial NCT04051333?

This trial is currently completed. The enrollment target is 87 participants. The study started on 2020-03-30. Estimated completion is 2021-12-31.

What conditions does trial NCT04051333 study?

This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.

What interventions are being tested in trial NCT04051333?

The interventions under investigation include: ALS Nutrition App (MyDataHelps platform) (DEVICE).

Who is sponsoring clinical trial NCT04051333?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04051333 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Amyotrophic Lateral Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.